Features

Features

CMO Moves: Regulatory catalysts for drug manufacturing – March 2023

Pharmaceutical Technology analyses recent regulatory and trial announcements that are likely to impact therapy manufacturing plans.

Manasi Vaidya and Fiona Barry

Features

Tapping into digital therapeutics to improve neurological outcomes

Features

Legal challenges put off label use of gender affirming care drugs in jeopardy

Features

Perimenopause: Tackling the dearth of treatments for anxiety and depression

Features

Dawn of a new indication: How to study drugs for aging

Features

Magazine: ‘Right shoring’ API production in Europe

Features

CMO Moves: Regulatory catalysts for drug manufacturing- February

Features

Is the microbiome therapy hype up for a reckoning?

Features

The one-shot cervical cancer vaccine paradigm

Natasha Spencer-Jolliffe

Features

FDA drug dosage optimisation guidelines signal clinical trial reform

Features

How epilepsy researchers are moving the needle past anti-seizure treatments

Features

HIV vaccines suffer setbacks but new approaches could turn the tide

Features

Magazine: CRISPR gene therapies cut through in 2023

Features

Race to the finish: pharma edges closer to approval with RSV vaccines

Features

Money moves: How the biotech market is weathering inflationary storms

Features

Can the FDA keep the momentum going for rare disease drug approvals?

Features

CMO Moves: Regulatory catalysts for therapy manufacturing -January

Manasi Vaidya and Fiona Barry

Features

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Natasha Spencer-Jolliffe

Features

Are we entering the era of biologics for COPD?

Natasha Spencer-Jolliffe

Features

CRISPR gene therapies: Is 2023 a milestone year in the making?

Features

Magazine: Humira biosimilars set the stage for long-awaited 2023 US launches

Features

2022 in review: Tracking the ups and downs of pharma deals

Akosua Mireku and Irena Maragkou

Features

2022 in review: Regulation starts to catch up with AI in pharma

Features

What a mild recession could mean for small biotechs in 2023

Features

2022 in review: Drug development milestones for tropical diseases

Features

CMO Moves: Regulatory catalysts for drug manufacturing-December

Manasi Vaidya and Fiona Barry

Features

Alzheimer’s disease biomarkers galvanise rocky drug development space

Features

Humira biosimilars set the stage for long-awaited 2023 US launches

Features

CMO Moves: Regulatory catalysts for drug manufacturing-November

Manasi Vaidya and Fiona Barry

Features

The “Medical Bypass”: New drugs to strike obesity

Features

Ketamine: Could this anesthetic be the key to treating neurological disorders?

Features

Magazine: What Rishi Sunak can do for the UK pharma industry

Features

What do companies need from COP27?

Features

Artificial intelligence hiring levels in the pharma industry dropped in October 2022

Data Journalism Team

Features

Internet of things hiring levels in the pharmaceutical industry dropped in October 2022

Data Journalism Team

Features

The pharmaceutical industry found it easier to fill artificial intelligence vacancies in Q3 2022

Data Journalism Team

Features

COP27: Mattie Yeta, CGI’s chief sustainability officer, on the first-ever ‘metaverse COP’

Features

COP27: How countries compare on carbon emissions and pledges